News
Moderna's New Lower-Dose COVID-19 Vaccine Approved by FDA
By Stephanie Brown HealthDay ReporterTUESDAY, June 3, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved a new lower-dose vaccine for active immunization against COVID-19 caused by severe acute respiratory syndrome coronavirus 2.
Moderna's new COVID-19 vaccine mNexspike approved by FDA, but there's a limit on who can use it
The FDA's approval was based on a study of 11,400 people age 12 and older that compared the new low-dose vaccine with Moderna's existing vaccine. It found the new vaccine was safe and was at least as effective - and more by some measures - than the original shot, the company said.
Moderna convinced a U.S. appeals court on Wednesday to uphold a ruling that undercut patent infringement claims by biotech ...
Moderna Inc. has agreed to do a placebo-controlled trial of its new Covid vaccine that was recently approved by US regulators ...
Moderna (NASDAQ: MRNA) stock represented the ticket to an investing win. The company brought its coronavirus vaccine from ...
Moderna’s newest lower-dose COVID-19 vaccine is approved for all adults 65 and older, and for people aged 12 to 64 who are at ...
The biotech’s mRNA vaccines were lauded by the first Trump administration but now are caught up in government changes to ...
The biotech giant that soared during Operation Warp Speed now faces regulatory hurdles, political scepticism, and dwindling ...
The Trump administration has canceled $766 million awarded to Moderna to develop a vaccine against potential pandemic ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback